Vasudha Tandon

AI is a viable alternative to high throughput screening: a 318-target study

Izhar Wallach, Denzil Bernard, Kong T. Nguyen et al. · Scientific Reports · 2024 · 120 citations · Full text

Pharmacy, Bioinformatics, Medicinal Chemistry +16

Inhibition of dual-specificity tyrosine phosphorylation-regulated kinase 2 perturbs 26S proteasome-addicted neoplastic progression

Sourav Banerjee, Tiantian Wei, Jue Wang et al. · Proceedings of the National Academy of Sciences · 2019 · 61 citations · Full text

Medicine, Oncology, Pharmacology +15

Synthesis of <i>N</i> -(4-chlorophenyl) substituted pyrano[2,3-c]pyrazoles enabling PKBβ/AKT2 inhibitory and <i>in vitro</i> anti-glioma activity

Ruturajsinh M. Vala, Vasudha Tandon, Lynden Guy Nicely et al. · Annals of Medicine · 2022 · 28 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +14

Syrbactin-class dual constitutive- and immuno-proteasome inhibitor TIR-199 impedes myeloma-mediated bone degeneration <i>in vivo</i>

Vasudha Tandon, Ruturajsinh M. Vala, Albert Chen et al. · Bioscience Reports · 2022 · 21 citations · Full text

Medicine, Molecular Biology, Oncology +13

Dual inhibition of HSF1 and DYRK2 impedes cancer progression

Vasudha Tandon, Rita Moreno, Kira Allmeroth et al. · Bioscience Reports · 2023 · 15 citations · Full text

Medicine, Cancer Biology, Oncology +17